<DOC>
	<DOCNO>NCT00113815</DOCNO>
	<brief_summary>The purpose study evaluate tolerability , safety efficacy topiramate infant refractory partial onset seizure ( POS ) .</brief_summary>
	<brief_title>Topiramate Adjunctive Therapy Infants 1-24 Months Control Partial Onset Seizures</brief_title>
	<detailed_description>This world wide , multicenter , randomize , double-blind , placebo-controlled study evaluate tolerability , safety efficacy 3 target dos ( 5 , 15 , 25 mg/kg/day ) topiramate compare placebo adjunct therapy infant refractory partial onset seizure ( POS ) . There 4 phase study , screen phase 3 day , double blind treatment phase 20 day , one year open label extension phase posttreatment ( taper withdrawal ) phase . The oral liquid formulation also assess study , investigational , unlike market sprinkle formulation . 5 , 15 , 25 mg/kg/day topriramate sprinkle oral liquid formulation administer four phase study .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>124 month , inclusive Concurrent 1 2 antiepileptic drug Receiving regular enteral feeding Weigh 3.5 15 kg Clinical EEG evidence simple complex POS Exclusively breast fed take medicine mouth Surgically implant function vagus nerve stimulator Renal stone Medically uncontrolled illness condition Infantile seizures result correctable medical condition Progressive neurologic disorder</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Partial seizure disorder</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Infants</keyword>
</DOC>